Macrogenics INC 8-K filings

NASDAQ

3 Apr 2024

MGNX

8-K: MacroGenics Provides Update on Phase 2 TAMARACK Study, Plans for Future Data Releases

MacroGenics announced early interim safety data from its Phase 2 TAMARACK study of vobramitamab duocarmazine, with plans to release further data in the coming months.

NASDAQ

7 Mar 2024

MGNX

Macrogenics INC

8-K: MacroGenics Reports 2023 Financial Results and Provides Corporate Update, Highlighting Pipeline Advancements

MacroGenics announced its 2023 financial results and provided an update on its clinical pipeline, including the completion of enrollment in the TAMARACK Phase 2 study and the initiation of a Phase 1 study for MGC026.